JSC „Grindeks” informs on business analysis regarding manufacturing expansion and establishment of injection plant. The purchase of the injections manufacturing company is another option for expansion that is still on the agenda. Any decisions regarding establishment or purchase of the injection plant are not taken yet. At the moment injections are produced under the contract manufacturing agreements in pharmaceutical companies in Lithuania, Poland and Slovakia. „Grindeks” believes that it will keep the current growth dynamics in existing and new markets and finish the year 2009 successfully with up to 78 million lats turnover. „Grindeks” works actively to complete the registration process of the brand product Mildronate® in China until the end of 2009. The positive result will depend on decisions of China State Food and Drug Administration agency whether to carry out additional research of Mildronate® technology. About “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States. The main directions of its operation are research, development, manufacturing and sales of original products, as well as generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, psychotropic and anti-cancer therapeutic groups of medications. „Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia; as well as representatives and representative offices in 14 countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as Japan and USA. The shares of JSC „Grindeks” are listed in the Official List of „NASDAQ OMX Riga”. Further information: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: (+371) 67083370, (+371) 29256012 Fax: (+371) 67083505 E-mail: laila.klavina@grindeks.lv